Device Trial Radar · NCT07934563
Single-Arm Trial of Carotid Stenting for Carotid Stenosis (Timing Trial)
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
208
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Dec 1, 2028
Study completion Dec 1, 2028
Sponsor
- Lead sponsor
- Suzhou Zenith Vascular SciTech LimitedNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Xuanwu Hospital, Beijing
- First posted
- Nov 13, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multicenter, single-group, target value clinical trial planning to enroll 208 eligible subjects. Participants will be treated with the investigational carotid artery stent system and followed up at discharge, 30 days, 6 months, and 12 months postoperatively to evaluate the safety and efficacy of the device for endovascular treatment of carotid artery stenosis.
Conditions
- Carotid Artery Stenosis
- Carotid Artery Stenosis Asymptomatic
- Atherosclerosis
Interventions
Carotid Artery StentingDevice
All participants will undergo carotid artery stenting (CAS).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of In-Stent Restenosis (ISR)Time frame: through study completion, an average of 1 year
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xuanwu Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.